

### TEXAS Health and Human Services

# **COVID-19 Update**

### September 21, 2021

John W. Hellerstedt, MD, Commissioner Jennifer Shuford, MD, MPH, Chief State Epidemiologist Texas Department of State Health Services



# **COVID-19 Snapshot**



### **Snapshot: COVID-19 in Texas**

### As of September 20, 2021

- Total Cases:
  - 3,283,785
  - 7-day average for new daily cases is decreasing
- Current Hospitalizations:
  - 11,710 (trending down)
- Total Fatalities:
  - 60,832
  - 7-day average of new fatalities is slowly decreasing
- Molecular Positivity Rate:
  - 15.65%

| ing |  |
|-----|--|
|     |  |
|     |  |
|     |  |
|     |  |



**Texas Department of State** 

Health Services



# **DSHS Response Activities**



# **DSHS Roles during the Pandemic**

- Coordinate state and local public health efforts.
- Deploy medical staffing to hospitals, nursing facilities, and other healthcare entities.
- Source and allocate therapeutics, medical supplies, and personal protective equipment.
- Maintain public awareness and knowledge through multi-media platforms.
- Provide guidance for individuals, businesses, and elected leaders.
- Manage lab testing and capacity.
- Collect, analyze, and report data.
- Develop the infrastructure for equitable COVID-19 vaccine distribution.



## **Medical Surge Staff**





- DSHS has mobilized 7,456 medical surge staff across Texas
  - Over 8,000 will be deployed by 9/17/2021
- 158 medical surge staff have been deployed to children's hospitals to support increased COVID-19 pediatric patients
- 112 medical surge staff have been placed in Labor & Delivery units in hospitals across the state

# **Durable Medical Equipment and Resources**



DSHS has deployed durable medical equipment (DME) to 196 facilities across Texas

- 3,390 total DME deployed to hospitals including:
  - 209 Cardiac Monitors
  - 311 High Flow Oxygen System
  - 572 IV Pumps
  - 594 O2 Concentrators
  - 1,037 Ventilators
- 9 Trailers deployed across Texas
- 2 ambulances to support EMS

2339 vaccines administered to homebound individuals and household members



### **DSHS Support Activities**

- DSHS COVID-19 Hotline: 2-1-1 Option 6 or coronavirus@dshs.Texas.gov
  - Operates Monday Friday 8 AM 5 PM CST, Saturday 8 AM – 1 PM CST, closed on Sundays
  - 3,273 calls received from 6/26/21 9/14/21
  - 2,638 emails received from 6/26/21 9/14/21
- Provider Webinars Tuesday & Thursdays
- Bi-weekly Tuesday Statewide Calls for local and regional healthcare professional





Texas Department of State



# **Monoclonal Antibody Therapeutics**



# Monoclonal Antibody Therapy

- DSHS Regional Infusion Centers (RICs)
  - 13,877 total infusions administered at DSHS RICs
  - Additional state infusion centers and +200 private infusion centers
- Criteria to receive monoclonal antibody therapy:
  - Doctor's order
  - Pediatric patients 12 17 years and weighing at least 40 kg
- Supply at the federal level has decreased, and shipments to states will decrease
  - Federal allocations to states based on population, cases and hospitalizations, and adherence to reporting
  - DSHS implementing an equitable allocation strategy
- DSHS Therapeutics Hotline for Providers:
  - <u>therapeutics@dshs.texas.gov</u>





# **School Data**



### **Texas School Data**

#### TEA School Data Reported to DSHS between 7/27/2020 - 8/29/2021

- 1,086 reported outbreaks
- 143,563 number of students infected
- 55,145 staff infected
- 198,708 total number of cases

#### **Data Reporting Limitations**

- Time lapse in reporting
- Variability in reporting, frequency, and completeness





Texas Department of State Health Services

### • Texas Public Schools COVID-19 Data Dashboard

# **DSHS Supporting Schools**

- DSHS was awarded approximately \$800 million in grants for public and private schools to:
  - Support screening testing to reopen and keep schools operating safely
  - *Note*: Houston received their own grant award
- DSHS and Texas Education Agency have been working closely to develop an implementation strategy
- School systems will have access to vendors to provide both rapid antigen and PCR test and staffing support






# Dr. Jennifer Shuford, MD, MPH Chief State Epidemiologist






# A Closer Look at Epidemiolocal Trends





New Texas Fatalities by Day







**Texas Department of State** 

**Health Services** 

#### **Texas Hospitalizations Over Time**


EXAS

ervices

**Texas Department of State** 

**Health Services** 


Pop: 29.7M; Slope: -188.2; 100k: -0.6; 7 Day Avg: 12,379.4; 7/14 Day Avg Δ: -150.5/-98.4




Blue line is 7 Day Moving Average. Δ is the change in the 7 Day Moving Average over a 7 or 14 day period. These preliminary data are current as of Mon Sep 20 13:16:37 202118











#### Statewide: 7-Day Rolling Average of 24-Hour Lab Confirmed COVID Admissions by Age

### **Pediatric Hospitalizations**





TEXAS Health and Human Services

### **New Hospital Admits Dashboard**

Pediatric COVID-19 Patients

257

in Hospitals

Molecular Tests

Antigen Tests

Confirmed COVID-19

2,727

Patients on Ventilators

#### Lab-Confirmed COVID-19

Adult COVID-19 Patients

3,554

in ICU Beds

# 11,838 **COVID-19 Inpatients**

Number of COVID-19 Hospitalizations 20.000 1/1 Apr Jul Apr Hospital Availability **Total Staffed Hospital Beds Total Staffed Inpatient Beds Available Ventilators** 61,056 65,496 6.459 **Available Staffed Hospital Beds** Available Staffed Adult ICU Beds Available Staffed Pediatric ICU Beds 7,583 304 86

About the Data

COVID-19 Case

Data

Tests by County

Admissions Previous 24 Hours

1,305

Confirmed COVID-19

Hospitals - Statewide

Adult COVID-19 Patients

8.027

in General Beds

Hospitals - Regional


Testing Data

Disclaimer: All data are provisional and subject to change. This dashboard will be updated daily by 4:00 PM CT.

23

Last Updated

9/19/2021 12:50 PM CT




#### Notes:

 After 7/23/2020, DSH5 reported incomplete hospitalization numbers due to a transition in reporting to comply with new federal requirements. As of 8/19/2020, 91% of hospitals were reporting.

 During the week of Feb. 14-Feb. 21, 2021, case and fatality reporting was significantly impacted across the majority of Texas counties due to weather-related issues.

Hospitalization data are missing or incomplete for 5/10/2021 and 5/11/2021

#### Total Texas Covid-19 Fatalities




Note: As of July 27, 2020, DSHS is reporting COVID-19 fatality data based on death certificates. The metric used in these charts reports total newly reported fatalities (as opposed to the date of death).



### COVID-19 Fatalities by Age: N = 60,832

20000


- Majority of COVID-19 associated fatalities are among Texans 50+
- Proportion of fatalities under 50 has grown since January
  - From May 16 to August 7, almost 20-percent of fatalities were in individuals between 0 – 49 years




\*as of September 17, 2021

### **COVID-19 Fatalities Demographics**

# Race/Ethnicity as a Percentage of COVID-19 Fatalities





26






# **Reinfections & Breakthrough Cases**



### **Reinfections in Texas**

- When an individual becomes infected with COVID-19, and then becomes reinfected
  - Most reinfection cases in Texas are in individuals 50 years and under
- Variability of natural immunity; protection that vaccines offer is preferred
- A total of 1,078 confirmed reinfections reported to DSHS between 1/1/2021 – 9/8/2021
  - 8.9% of total cases were hospitalized during their reinfection
  - 117 total reinfection cases in 0 19 years of age
  - 168 total reinfection cases in 20 29 years of age (highest rate)





# **Vaccine Breakthrough Cases in Texas**

- Fully vaccinated status is 14 days after completion of vaccine primary series and is required to meet criteria to be considered a vaccine breakthrough
- As the number of people who are vaccinated increases, the number of breakthrough cases is also expected to in increase
- DSHS collects information on breakthrough cases that require hospitalization or result in fatality (per new CDC reporting request)
- 693 confirmed vaccine breakthrough cases of heightened public health interest (clinically severe) that resulted in hospitalization
  - Most were 60 and older
  - 119 fatalities: 101 were in those 60 and older, and 89 had reported a known underlying health condition






# **Epidemiolocal Trends:** MIS-C



# Multisystem Inflammatory Syndrome in Children (MIS-C) in Texas

- MIS-C in Texas as of 9/20/2021:
  - 231 total confirmed cases
  - Age range: 7 months-18 years old (median 9 years old)
  - Sex: 150 Male (65%), 81 Female (35%)
  - Race/Ethnicity: 121 Hispanic (52%), 55 Black (24%), 38 White (16%), 6 Asian (3%), 11 Unknown (5%)
- Hospital and ICU admission:
  - 231 Hospitalized
  - 155 ICU admission (67%)
- Outcome:
  - 207 Discharged (90%)
  - 1 fatality (<1%)
  - 23 unknown/lost to follow-up (10%)





# **Epidemiolocal Trends: SARS-CoV-2 Variants**





Texas Department of State Health Services

|      |          |           |           | onne      | u ota   | tes. o  | 101201  | .1-0    | 11/20    | 121       |           |           |           |           |
|------|----------|-----------|-----------|-----------|---------|---------|---------|---------|----------|-----------|-----------|-----------|-----------|-----------|
|      |          |           |           |           |         |         |         |         |          |           |           |           | **        | **        |
| 100% | Other*   | Other     |           |           |         |         |         |         |          |           |           |           |           |           |
| 90%  | õ        | 9         |           | -         |         |         |         |         |          |           |           |           |           |           |
| 80%  |          |           | 1112      | 8.1.1.7   |         |         |         |         |          |           |           |           |           |           |
| 70%  | 14       | 8117      | 8         |           |         |         |         |         |          |           |           |           |           |           |
| 60%  | 8117     |           |           |           |         |         |         |         |          | 1         | ~         | N         | N         | N         |
| 50%  |          |           |           | 72        | 8.16172 | 8.16172 | 8.16172 | 8.16172 | 8:1617.2 | 8.1.617.2 | 8.1.617.2 | 8.1.617.2 | 8.1.617.2 | 8.1.617.2 |
| 40%  |          | -         | 8.1.617.2 | 8.1.617.2 | 1.8     | 8       |         |         |          |           |           |           |           |           |
| 30%  | 8.1.6172 | 8.1.617.2 | œ         |           |         |         |         |         |          |           |           |           |           |           |
| 20%  |          |           |           |           |         |         |         |         |          |           |           |           |           |           |
| 10%  | Fd       | Γd        | 174       |           |         |         |         |         |          |           |           |           |           |           |
| 0%   |          | -1        | -         | P.1       | -       |         | -       |         |          |           |           |           |           | -         |
|      | 6/12/21  | 6/19/21   | 6/26/21   | 7/3/21    | 7/10/21 | 7/17/21 | 7/24/21 | 7/31/21 | 8/7/21   | 8/14/21   | 8/21/21   | 8/28/21   | 9/4/21    | 12/11/6   |

United States: 6/6/2021 - 9/11/2021

United States: 9/5/2021 - 9/11/2021 NOWCAST

| USA       |           |      |        |             |  |
|-----------|-----------|------|--------|-------------|--|
| WHO label | Lineage # | Туре | %Total | 95%PI       |  |
| Alpha     | B.1.1.7   | VOC  | D.0%   | 0.0-0.2%    |  |
| Beta      | B.1.351   | VOC  | 0.0%   | 0.0-0.2%    |  |
| Gamma     | P.1       | VOC  | 0.0%   | 0.0-0.2%    |  |
| Delta     | B.1.617.2 | voc  | 99.4%  | 98.6-100.0% |  |
|           | AY.1      | voc  | 0.2%   | 0.0-0.7%    |  |
|           | AY.2      | VOC  | 0.1%   | 0.0-0.5%    |  |
| Eta       | B.1.525   | VOI  | 0.0%   | 0.0-0.2%    |  |
| lota      | B.1.526   | VOI  | 0.0%   | 0.0-0.2%    |  |
| Карра     | B.1.617.1 | VOI  | 0.0%   | 0.0-0.2%    |  |
| Mu        | B.1.621   |      | 0.1%   | 0.0-0.5%    |  |
| N/A       | B.1.617.3 | VOI  | 0.0%   | 0.0-0.2%    |  |
| Other     | Other*    |      | 0.2%   | 0.0-0.7%    |  |

\* Enumerated lineages are VOI/VOC or are circulating >1% in at least one HHS region during at least one two week period; remaining lineages are aggregated as "Other".

\*\* These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates

# Sublineages of P.1, B.1.351 and B.1.621 are aggregated with the parent lineage and included in parent lineage's proportion. Q.1-Q.8 are aggregated with B.1.1.7. AY.3-AY.25 are aggregated with B.1.617.2, 33


Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed 9/17/2021.



# Impact of COVID-19 On Public Health



# Texas Vaccines for Children (TVFC) Childhood Non-Flu Vaccines




Texas Department of State Health Services


ervices

EXAS

### ImmTrac2 Flu Vaccine Administration by Flu Season



# Texas HIV Diagnoses (Sept-Aug rolling year)\*






Texas Department of State Health Services

#### \*Provisional Data pulled from eHARS

### **Changes in DSHS-funded HIV Testing Programs**

# Testing by HIV prevention contractors, 2017-2018

# Partner testing during HIV or syphilis, 2017 -2020



# **Congenital Syphilis**

In 2020, Public Health Follow-Up (PHFU )programs reported:

- 60% experienced 50%-100% staff reassignment to COVID-19 related activities
- 50% did not conduct field activities, limiting the number of timely notifications and field-testing opportunities
- Over 50% reported local STI clinic closures or operating at reduced capacity, impacting timely treatment for persons with an infection and those exposed to an infection

#### PHFU programs continue to report:

- Pregnant persons hesitant when seeking prenatal care, delaying early engagement in prenatal care and third trimester testing
- Clients reporting concerns with access to emergency departments when penicillin desensitization is necessary to administer adequate treatment
- Limited access to hospital medical records impacted timely identification of CS cases






# **DSHS** Data Tools



# **Texas COVID-19 Data Tools**

- COVID-19 Texas Case Counts
  - County by county data
  - Filters display probable cases, estimated active, estimated recovered cases, and demographic fatality data
  - <u>ArcGIS Dashboards</u>
- <u>Texas Hospital Data Dashboard</u>
- Texas Data Vaccine Dashboard
  - Displays vaccine administration throughout the state
  - Tabs display demographic data, vaccines allocated, and sites of vaccinations
  - <u>Workbook: COVID-19 Vaccine in Texas (Dashboard)</u>
- Information for Hospital and Healthcare Professionals
  - Various FAQs and resources for providers on topics ranging from COVID-19 vaccines to COVID-19 Therapeutics
  - <u>https://dshs.texas.gov/coronavirus/healthprof.aspx#thera</u>
- COVID-19 Variants Tracker
  - https://dshs.texas.gov/news/updates.shtm#coronavirus







### dshs.texas.gov/coronavirus

Follow TexasDSHS on <u>Twitter</u>, <u>Facebook</u>, <u>YouTube</u> and <u>Instagram</u> or visit <u>www.dshs.texas.gov</u>